Pfizer has announced the creation of a rare disease research unit, focusing on discovering medicines for diseases affecting less than 200,000 patients. Of the more than 6,000 diseases classified as “orphan” (of which ALS is one), fewer than 10% have therapies that directly address the underlying disease. “Pfizer’s Rare Disease Research Unit will pursue treatments across all therapeutic areas and modalities and will serve as the focal point for the company’s existing research on rare diseases,” reports FierceBiotech. The Rare Diseases Research Unit will be lead by Edward Mascioli, M.D., the founder and former CEO of Dapis Capital, a private equity firm focused on healthcare and the life sciences.
Click here to read more.Share this: